Key result
Botulinum toxin type A is linked to reduced post-stroke motion-related shoulder pain over 4 months.
Observational (n=16)
Answers are grounded in this paper and cite their sources.
Shows reduced pain during shoulder motion after botulinum toxin type A injections in post-stroke patients, indicating a safe and efficacious therapeutic option.
Botulinum toxin type A (BTX-A) has been used to treat several neurological conditions such as sialorrhea, hyperhydrosis, dystonia, hemifacial spasm, spasticity and pain. Although spasticity has been successfully treated with BTX-A, few are the authors studying the use of BTX-A to treat shoulder pain secondary to stroke. In order to study if BTX-A is effective to treat post-stroke shoulder pain, we followed up during 4 months 16 patients with sustained shoulder pain. Patients received BTX-A according to previous discussion with the rehabilitation group to determine the muscles and dose to be injected and were evaluated by the join range of motion and analogic pain scale. There was decrease of pain during shoulder motion, mainly during the movements of extension and rotation. We conclude that BTX-A is a safe and efficacious therapy.
No takes yet. Share an insight, caveat, or question.
Pedreira et al. (2008) conducted an observational in Refractory post-stroke shoulder pain (n=16). Botulinum toxin type A (BTX-A) was evaluated on Joint range of motion and analogic pain scale. Botulinum toxin type A decreased post-stroke shoulder pain during motion (mainly extension and rotation) in 16 patients over 4 months.
Synapse has enriched 10 related papers. Consider them for comparative context: